Pancreatic Cancer Research

ResearcherYamagata UniversityActive in the last 2 years

Toru Furukawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1083-2324; OpenAlex author ID A5012989108. Sources: OpenAlex.

Their work

Papers
45 (first author 1, last author 12)
Trials
0
Grants
0
Labs led
2
Collaborators
175
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 1 paper · 2014: none · 2015: 3 papers · 2016: 2 papers · 2017: 1 paper · 2018: 3 papers · 2019: 3 papers · 2020: 3 papers · 2021: 7 papers · 2022: 5 papers · 2023: 4 papers · 2024: 3 papers · 2025: 5 papers · 2026: 2 papers

Papers 45

  1. Histological treatment response to neoadjuvant chemotherapy predicts the survival outcomes of patients with resectable pancreatic cancer: validation of the Jap… Co-author DOI 10.1007/s00595-026-03325-w↗
  2. Comparative Study of Pathological and Imaging Findings in High-Grade Pancreatic Intraepithelial Neoplasia: A Multicenter Analysis by the Japan Study Group on E… Co-author DOI 10.1097/mpa.0000000000002710↗
  3. A case of FGFR2 fusion-positive pancreatic head tumor with difficult differential diagnosis between cholangiocarcinoma and pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12328-025-02193-0↗
  4. Clinical importance of suspicious for malignancy compared to positive for malignancy in peritoneal cytology for surgically resected pancreatic cancer. Co-author DOI 10.1016/j.pan.2025.05.006↗
  5. Transcriptional regulation of ETV5 by mitogen-activated protein kinase via ETS-1 in human pancreatic cancer cells. Last author DOI 10.1038/s41598-025-97166-1↗
  6. Clinicopathological Relevance of SMAD4 and RUNX3 in Patients With Resected Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000002429↗
  7. Three Molecular Developmental Pathways of Remnant Pancreatic Cancer After Resection: A Nationwide Project Study of Japan Pancreas Society. Last author DOI 10.1097/sla.0000000000006444↗
  8. Polyunsaturated fatty acids-induced ferroptosis suppresses pancreatic cancer growth. Co-author DOI 10.1038/s41598-024-55050-4↗
  9. Deep learning predicts the 1-year prognosis of pancreatic cancer patients using positive peritoneal washing cytology. Last author DOI 10.1038/s41598-024-67757-5↗
  10. Machine Learning of Histopathological Images Predicts Recurrences of Resected Pancreatic Ductal Adenocarcinoma With Adjuvant Treatment. Last author DOI 10.1097/mpa.0000000000002289↗
  11. GATA6 and CK5 Stratify the Survival of Patients With Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy. Last author DOI 10.1016/j.modpat.2023.100102↗
  12. Co-occurring IPMN and pancreatic cancer: the same or different? An overview from histology to molecular pathology. First author DOI 10.1136/jcp-2023-209012↗
  13. Reduced expression of phosphorylated ataxia-telangiectasia mutated gene is related to poor prognosis and gemcitabine chemoresistance in pancreatic cancer. Co-author DOI 10.1186/s12885-023-11294-3↗
  14. Long Non-Coding RNAs Associated with Mitogen-Activated Protein Kinase in Human Pancreatic Cancer. Last author DOI 10.3390/cancers15010303↗
  15. Concordance of the histological diagnosis of type 1 autoimmune pancreatitis and its distinction from pancreatic ductal adenocarcinoma with endoscopic ultrasoun… Co-author DOI 10.1007/s00428-021-03236-w↗
  16. Whole-exome Sequencing Reveals New Potential Susceptibility Genes for Japanese Familial Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000004213↗
  17. PP6 deficiency in mice with KRAS mutation and Trp53 loss promotes early death by PDAC with cachexia-like features. Co-author DOI 10.1111/cas.15315↗
  18. Impact of Tumor-Derived DNA Testing in Peritoneal Lavage of Pancreatic Cancer Patients with and Without Occult Intra-Abdominal Metastases. Co-author DOI 10.1245/s10434-021-10997-w↗
  19. Predictors of Long-Term Survival in Pancreatic Ductal Adenocarcinoma after Pancreatectomy: TP53 and SMAD4 Mutation Scoring in Combination with CA19-9. Co-author DOI 10.1245/s10434-022-11630-0↗
  20. Germline DNA damage repair gene mutations in pancreatic cancer patients with personal/family histories of pancreas/breast/ovarian/prostate cancer in a Japanese… Co-author DOI 10.1002/ags3.12482↗
  21. Impact of the controlling nutritional status score on severe postoperative complications of pancreaticoduodenectomy for pancreatic cancer. Co-author DOI 10.1007/s00423-021-02151-7↗
  22. Evaluation of the validity of pancreatectomy for very elderly patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00423-021-02170-4↗
  23. Evaluation of the significance of adjuvant chemotherapy in patients with stage ⅠA pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2021.01.024↗
  24. A deep learning model to detect pancreatic ductal adenocarcinoma on endoscopic ultrasound-guided fine-needle biopsy. Co-author DOI 10.1038/s41598-021-87748-0↗
  25. Evaluation of Early Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Receiving Gemcitabine Together With Nab-paclitaxel. Co-author DOI 10.21873/cdp.10053↗
  26. Genetic Mutations of Pancreatic Cancer and Genetically Engineered Mouse Models. Last author DOI 10.3390/cancers14010071↗
  27. Aberrant (pro)renin receptor expression induces genomic instability in pancreatic ductal adenocarcinoma through upregulation of SMARCA5/SNF2H. Co-author DOI 10.1038/s42003-020-01434-x↗
  28. Focal Parenchymal Atrophy and Fat Replacement Are Clues for Early Diagnosis of Pancreatic Cancer with Abnormalities of the Main Pancreatic Duct. Co-author DOI 10.1620/tjem.252.63↗
  29. Genetic Tracing of Clonal Expansion and Progression of Pancreatic Ductal Adenocarcinoma: A Case Report and Multi-Region Sequencing Analysis. Co-author DOI 10.3389/fonc.2020.00728↗
  30. Pathways of Progression From Intraductal Papillary Mucinous Neoplasm to Pancreatic Ductal Adenocarcinoma Based on Molecular Features. Co-author DOI 10.1053/j.gastro.2018.10.029↗
  31. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/00365521.2019.1624816↗
  32. Vasohibin-2 plays an essential role in metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.14041↗
  33. Multicenter study of early pancreatic cancer in Japan. Co-author DOI 10.1016/j.pan.2017.11.007↗
  34. Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41598-018-26526-x↗
  35. Hot water extract of Agaricus blazei Murrill specifically inhibits growth and induces apoptosis in human pancreatic cancer cells. Last author DOI 10.1186/s12906-018-2385-4↗
  36. Familial pancreatic cancer: Concept, management and issues. Co-author DOI 10.3748/wjg.v23.i6.935↗
  37. Specific MAPK-Associated MicroRNAs in Serum Differentiate Pancreatic Cancer from Autoimmune Pancreatitis. Co-author DOI 10.1371/journal.pone.0158669↗
  38. Germline mutations in Japanese familial pancreatic cancer patients. Last author DOI 10.18632/oncotarget.12490↗
  39. [Pancreatic cancer precursor lesions]. Co-author DOI 10.11405/nisshoshi.112.1457↗
  40. Impacts of activation of the mitogen-activated protein kinase pathway in pancreatic cancer. Co-author DOI 10.3389/fonc.2015.00023↗
  41. [Pathology of the pancreatic cancer]. Co-author PMID 25856979↗
  42. Clinical importance of Familial Pancreatic Cancer Registry in Japan: a report from kick-off meeting at International Symposium on Pancreas Cancer 2012. Co-author DOI 10.1007/s00534-013-0611-5↗
  43. MicroRNAs associated with mitogen-activated protein kinase in human pancreatic cancer. Last author DOI 10.1158/1541-7786.mcr-11-0035↗
  44. Targeting of MAPK-associated molecules identifies SON as a prime target to attenuate the proliferation and tumorigenicity of pancreatic cancer cells. Co-author DOI 10.1186/1476-4598-11-88↗
  45. Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Co-author DOI 10.1097/mpa.0b013e318215010c↗

Closest collaborators

The 25 strongest of 175 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michiaki Unno · 12 shared papers, 2020–2026 · strength 2.09
  2. Masamichi Mizuma · 10 shared papers, 2017–2026 · strength 1.69
  3. Yuko Omori · 9 shared papers, 2019–2025 · strength 1.49
  4. Masakazu Yamamoto · 9 shared papers, 2012–2025 · strength 1.27
  5. Kei Nakagawa · 7 shared papers, 2021–2025 · strength 1.16
  6. Atsushi Masamune · 7 shared papers, 2018–2026 · strength 1.06
  7. Katsuya Hirose · 4 shared papers, 2023–2025 · strength 0.84
  8. Yuriko Saiki · 4 shared papers, 2021–2025 · strength 0.79
  9. Takashi Kokumai · 4 shared papers, 2023–2025 · strength 0.72
  10. Wataru Izumo · 5 shared papers, 2019–2021 · strength 0.67
  11. Masahiro Shiihara · 5 shared papers, 2019–2021 · strength 0.67
  12. Shuichi Aoki · 3 shared papers, 2022–2026 · strength 0.63
  13. Takanori Morikawa · 4 shared papers, 2021–2023 · strength 0.59
  14. Masahiro Iseki · 3 shared papers, 2020–2026 · strength 0.58
  15. Yusuke Mizukami · 5 shared papers, 2019–2025 · strength 0.58
  16. Aya Noguchi · 3 shared papers, 2024–2025 · strength 0.57
  17. Daisuke Douchi · 3 shared papers, 2023–2026 · strength 0.56
  18. Tomohiko Ishikawa · 2 shared papers, 2023–2025 · strength 0.42
  19. Shimpei Maeda · 2 shared papers, 2024–2026 · strength 0.40
  20. Atsushi Kanno · 3 shared papers, 2018–2026 · strength 0.38
  21. Noriyoshi Fukushima · 3 shared papers, 2021–2025 · strength 0.38
  22. Kenichi Hirabayashi · 3 shared papers, 2021–2025 · strength 0.38
  23. Keiji Hanada · 4 shared papers, 2011–2026 · strength 0.36
  24. Sohei Satoi · 2 shared papers, 2025 · strength 0.35
  25. Yoshifumi Takeyama · 2 shared papers, 2025 · strength 0.35

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.